Open Orphan Plc (LON: ORPH) is a fast-growing niche CRO (Clinical Research Organisation) pharmaceutical services company. It is one of the leading global firms in the testing of vaccines and antivirals through the use of human challenge clinical trials. In 2019, it bought Venn Life Sciences Holdings Plc, an integrated drug development consultancy, in a reverse takeover. In January 2020, Open Orphan completed the merger with hVIVO Plc, a global player known for testing the effectiveness of antivirals, vaccines, and respiratory disease agents. Established in 2017 and led by a team of experienced professionals, the company has offices in London, Dublin, Paris and the Netherlands. It is a part of the FTSE AIM All-Share.